Previous 10 | Next 10 |
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and six months ended June 30, 2020. As of ...
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good way to enter th...
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020, at 9:00 a.m. Easte...
Odonate Therapeutics (NASDAQ: ODT ): Q1 GAAP EPS of -$0.99 beats by $0.01 . More news on: Odonate Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31, 2020. As of March 31, 2020, Odo...
Odonate Therapeutics (NASDAQ: ODT ): Q4 GAAP EPS of -$0.91 beats by $0.11 . More news on: Odonate Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2019. As of Decem...
Amedisys (NASDAQ: AMED ) initiated with Market Perform rating and $170 (3% upside) price target at BMO. More news on: Amedisys, Inc., Athenex, Inc., Gossamer Bio, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Odonate Therapeutics (NASDAQ: ODT ): Q3 GAAP EPS of -$0.88 beats by $0.16 . More news on: Odonate Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and nine months ended September 30, 2019. As of Septem...
News, Short Squeeze, Breakout and More Instantly...
Odonate Therapeutics Inc. Company Name:
ODT Stock Symbol:
NASDAQ Market:
Odonate Therapeutics Inc. Website:
Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the c...
ODONATE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Odonate Therapeutics, Inc. - ODT ODONATE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, L...
Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders. This action is in connection with the Company’s previously announced decision to discontinue the deve...